Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Heiguteng Zhuifeng Huoluo Capsule (HZFC) is a multi-component traditional Chinese medicine used for the treatment of rheumatoid arthritis and cold arthralgia syndrome. As a Miao ethnomedicine, it is derived from multiple herbal sources, including Sinomenium acutum, Periploca forrestii, and Lygodium paridiformis stenophylla Franch. Studies have identified over 80 chemical constituents, primarily alkaloids, phenylpropanoids, and steroids. The key active alkaloids include sinomenine, dihydrosinomenine, and magnoflorine. The therapeutic effect is believed to stem from its anti-inflammatory properties, which involve the inhibition of NF-κB expression and other inflammatory pathways, leading to a reduction in joint inflammation and providing analgesic effects. It has been marketed in China for many years. [1, 3]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Heiguteng Zhuifeng Huoluo Capsule.